Furthermore, analysis of metastatic dynamics revealed that patients with a higher frequency (≥2%) of CD44+/CD24- CSCs usually developed distant metastasis earlier than those with < 2% of CD44+/CD24- and >19.5% of CD44-/CD24- tumor cells (the C1 group, Figure 1D). This evidence concerns the gene CD44 and neoplasm.